Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Increases By 163.0%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 40,500 shares, a growth of 163.0% from the September 30th total of 15,400 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 12,300 shares, the days-to-cover ratio is presently 3.3 days.

Cumberland Pharmaceuticals Stock Performance

Shares of NASDAQ CPIX opened at $1.22 on Monday. The company has a market capitalization of $17.31 million, a PE ratio of -2.07 and a beta of 0.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.26 and a current ratio of 1.44. The company’s fifty day moving average price is $1.29 and its 200 day moving average price is $1.43. Cumberland Pharmaceuticals has a 1 year low of $1.19 and a 1 year high of $2.36.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Cumberland Pharmaceuticals in a report on Friday. They issued a “hold” rating for the company.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.